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17β-hydroxysteroid dehydrogenaseMembrane proteins of the endoplasmic reticulum (ER) are involved in awide array of essential cellular functions.
Identiﬁcation of the topology of membrane proteins can provide signiﬁcant insight into their mechanisms of ac-
tion and biological roles. This is particularly important for membrane enzymes, since their topology determines
the subcellular site where a biochemical reaction takes place and the dependence on luminal or cytosolic co-
factor pools and substrates. The methods currently available for the determination of topology of proteins are
rather laborious and require post-lysis or post-ﬁxation manipulation of cells. In this work, we have developed
a simple method for deﬁning intracellular localization and topology of ER membrane proteins in living cells,
based on the fusion of the respective proteinwith redox-sensitive green-ﬂuorescent protein (roGFP).Wevalidat-
ed the method and demonstrated that roGFP fusion proteins constitute a reliable tool for the study of ER mem-
brane protein topology, using as control microsomal 11β-hydroxysteroid dehydrogenase (11β-HSD) proteins
whose topology has been resolved, and comparing with an independent approach. We then implemented this
method to determine the membrane topology of six microsomal members of the 17β-hydroxysteroid dehydro-
genase (17β-HSD) family. The results revealed a luminal orientation of the catalytic site for three enzymes,
i.e. 17β-HSD6, 7 and 12. Knowledge of the intracellular location of the catalytic site of these enzymes will enable
future studies on their biological functions and on the role of the luminal co-factor pool.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Endoplasmic reticulum(ER)-resident proteins are pivotal in an array
of cellular functions, including protein synthesis and folding, disulﬁde
bond formation, glycosylation and enzymatic processing of substrates.
A fraction of these proteins is attached to the ER membrane through
one (single-spanning membrane proteins) or multiple (polytopic pro-
teins) transmembrane regions, or through a speciﬁc region that does
not transverse the membrane, but loosely attaches to it through hydro-
phobic interactions. An intact topology of membrane proteins, i.e. their
orientation in relation to themembrane, is crucial for their function and
depicts important aspects of their physiology. Regarding ER enzymes,
the catalytic site as well as the co-factor binding site can face either
the ER lumen or the cytosol, which dictates the source site of substrategenase;17β-HSD,17β-hydroxy-
ransferase; DTT, dithiothreitol;
lasmic reticulum; GFP, green-
ent protein; ROI, region of inter-
ystems Toxicology, Department
ergstrasse 50, CH-4056 Basel,
5.
t).and co-factor and, hence, the site of biochemical reactions. In addition,
the topology of ER enzymes deﬁnes the subcellular site of post-
translational modiﬁcations and interactions with other proteins,
which are crucial for their biological functions.
Several methods have been developed for the determination of the
topology of ER membrane proteins. Among them, the proteinase K
protection assay is a commonly used biochemical method, which
includes isolation of microsomal membranes, followed by cleavage of
exposed protein domains by the proteinase and immuno-detection of
the remaining protein fragment (for examples, see Refs. [1–5]). This
method is multi-step and laborious, and its credibility relies vastly on
the quality of the microsomal preparation (e.g. on the percentage of
inside-out orientation of the microsomal vesicles), as well as on the
purity and activity of proteinase K. Another method used for the deter-
mination of the topology of ER membrane proteins is the selective per-
meabilization of cell membranes with speciﬁc detergents, such as
digitonin [6–10] and saponin [11,12] or pore-forming agents, such as
streptolysin-O [13–15], followed by immunoﬂuorescence staining. The
most commonly used reagent is digitonin, which permeabilizes a lipid
bilayer by binding to cholesterol molecules that are much more abun-
dant in the plasmamembrane than in the ERmembrane. Since the cho-
lesterol content can signiﬁcantly vary depending on the cell type, state
and passage number, the success of this method relies on the duration
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Non-optimal conditions can lead to complete permeabilization of cell
membranes. In addition, since partial permeabilization of ER mem-
branes can occur, statistical analysis of the percentage of cells positive
with digitonin in comparison with a detergent that fully penetrates all
cell membranes (such as Triton X-100) is mandatory. For this purpose,
proteins known to face the ER lumen or the cytosol should be included
in the experiments as positive/negative controls.
Additionally, ﬂuorescence-based methods to determine membrane
protein topology have been developed, such as the ﬂuorescence prote-
ase protection assay, which is, however, also based on selective perme-
abilization of cell membranes with digitonin [16,17]. The bimolecular
ﬂuorescence complementation assay is another method employed for
topology determination [18], involving fusion of the protein of interest
with the non-ﬂuorescent half of yellow-ﬂuorescent protein (YFP), and
targeting of the other non-ﬂuorescent half to the ER. This method re-
quires spatial proximity of the two halves of YFP, as well as optimal con-
formational orientation, which then allows the full-length YFP protein
to be formed, conditions that are often not fulﬁlled.
In order to develop a straightforward and reliable method for the
determination of the topology of ER membrane proteins, we took ad-
vantage of the recently engineered redox-sensitive green ﬂuorescent
protein (roGFP) [19–21]. In roGFP two amino acids (aa) of the wild-
type GFP have been substituted by cysteine residues. Depending on
whether these cysteine residues form an intramolecular disulﬁde
bond or not, the emission peaks of roGFP after excitation at 405 nm
and 488 nm change in their intensity. The ratio of ﬂuorescence intensity
at these twowavelengths can be used to calculate the percentage of the
oxidized form of roGFP in real-time. The ratiometric nature of roGFP
renders it independent of parameters such as absolute probe concentra-
tion. We reasoned that fusion of roGFP at the C-terminus of a protein
and measurement of roGFP oxidation would reﬂect whether this part
of the protein resides in an oxidizing environment (ER lumen) or a
reducing environment (cytosol). To date, roGFP proteins with slight
differences in their aa sequence and variants of those, exhibiting dis-
crete ﬂuorescence properties, have been developed (roGFP1–roGFP6)
[19–21]. For our experiments, we constructed fusions with roGFP2,
since this variant shows a moderate oxidation in the ER at steady state
[22]. roGFP2 shows a major peak at 488 nm in the reduced form,
while in the oxidized form the peak is higher at 405 nm. Grx1–roGFP2
and Orp1–roGFP2 fusions have been successfully used as reporters of
glutathione redox potential [23,24] and H2O2 [25,26] content, respec-
tively. However, the use of roGFP2 has not been established for topology
assessment.
Here, as proof of principle, we constructed fusion of roGFP2with the
two microsomal enzymes 11β-HSD1 and 11β-HSD2, which have been
shown to face the luminal and cytosolic compartment, respectively
[27–30]. We then implemented this method to unravel the intracellular
localization and membrane topology of enzymes belonging to the 17β-
hydroxysteroid dehydrogenase (17β-HSD) family [31,32]. 17β-HSD
enzymes catalyze the reduction/oxidation at the position 17 of the ste-
roid backbone of androgens and estrogens, thus playing a key role in the
control of the balance of active and inactive sex steroids. Many 17β-
HSDs have been implicated in different forms of sex-speciﬁc cancer
[33–36] and 17β-HSD inhibitors have lately attracted considerable in-
terest as therapeutic targets [32,37–40]. Several members of this family
are multifunctional and are involved in other essential biochemical re-
actions, such as the elongation of very long chain fatty acids [41], choles-
terol synthesis [42] and peroxisomal β-oxidation of fatty acids [43].
Thus, the elucidation of the functions of these enzymes requires further
research.
In this paper, by fusing roGFP2 with a protein of interest, we were
able to develop a simple, non-invasive and reliable method to assess
the topology of ER membrane proteins in living cells. This method
could prove useful as a tool to resolve the topology of any ERmembrane
protein.2. Materials and methods
2.1. Cell culture and transient transfection
HEK-293 cells were cultured at 37 °C and 5% CO2 in Dulbecco's mod-
iﬁed Eagle's medium (DMEM) containing 2mM L-glutamine, 4.5 mg/ml
glucose, and supplemented with 10% fetal bovine serum, 100 U/ml pen-
icillin, 100 μg/ml streptomycin, 10 mM HEPES buffer pH 7.4 and non-
essential amino acid solution. All cell culture materials were purchased
from Sigma-Aldrich (Buchs, Switzerland). The transfections were per-
formed using the calcium phosphate precipitation method [44]. For
the triggering of lipid-droplet formation, oleic acid at a ﬁnal concentra-
tion of 150 μΜwas added on cells 16 h prior to immunostaining.
2.2. Molecular cloning and expression constructs
To generate roGFP2 fusion proteins with human 11β-HSD1
(SDR26C1), 11β-HSD2 (SDR9C3), 17β-HSD1 (SDR28C1), 17β-HSD2
(SDR9C2), 17β-HSD2 (aa 1–88), 17β-HSD6 (SDR9C6), 17β-HSD6 (aa
1–35), 17β-HSD7 (SDR37C1), 17β-HSD11 (SDR16C2), 17β-HSD11 (aa
1–42), 17β-HSD12 (SDR12C1), 17β-HSD12 (aa 1–56), and 17β-HSD13
(SDR16C3), 17β-HSD13 (aa 1–42) we ﬁrst subcloned roGFP2 into the
pcDNA3vector (Life Technologies, Zug, Switzerland) between the endo-
nuclease restriction sites EcoRV and XbaI. A linker sequence (TCAGGA
GGA) was added upstream of the roGFP2 sequence. The coding se-
quences of the above genes were ampliﬁed from donor vectors by PCR
and subcloned upstream of roGFP2. 11β-HSD1, 17β-HSD1, 17β-HSD2,
17β-HSD2 (aa 1–88), 17βHSD7 and 17β-HSD11 were subcloned be-
tween the KpnI/EcoRV restriction sites. 17β-HSD6, 17β-HSD6 (aa 1–35),
17β-HSD12, 17β-HSD12 (1–42), 17β-HSD13, 17β-HSD13 (aa 1–42)
and 11β-HSD2 were subcloned between HindIII/EcoRV and 17β-HSD11
(aa 1–42) between BamHI/EcoRV restriction sites. This strategy allowed
the expression of C-terminally roGFP2-tagged proteins with a three aa
linker (SGG, single letter aa code) between the protein of interest and
roGFP2.
All of the full length ﬂag-tagged constructs used for selective perme-
abilization experiments were produced by PCR ampliﬁcation of the
coding sequence from donor vectors and subcloned into the pcDNA3
vector. These constructs are: 11β-HSD1-FLAG, 11β-HSD2-FLAG, 17β-
HSD2-FLAG, 17β-HSD6-FLAG, 17β-HSD7-FLAG, 17β-HSD11-FLAG,
17β-HSD12-FLAG and 17β-HSD13-FLAG. The sequence encoding the
FLAG peptide was added to the oligonucleotide primers downstream
of the coding sequence of the corresponding gene, for the production
of C-terminally tagged proteins. For the N-terminally tagged 17β-
HSD7 (FLAG-17β-HSD7) the FLAG epitope was added upstream of the
coding sequence. All constructs were veriﬁed by sequencing. Primer se-
quences are available upon request.
2.3. Selective permeabilization and indirect immunoﬂuorescence
experiments
HEK-293 cells were seeded on glass coverslips and were transiently
transfected after 24 h. At 48 h post-transfection cells werewashed twice
with PBS, ﬁxed with 4% paraformaldehyde solution for 15 min and
washed three times with PBS. For selective permeabilization of cell
membranes, cells were incubated with 14 μΜ digitonin for 3 min.
Complete permeabilization of all cell membraneswas achieved by incu-
bation of cells with 0.3% Triton X-100 for 5 min. After washing, blocking
solution containing 2% defattedmilk was added for 30min, followed by
incubation with primary antibody for 1 h. The antibodies used were
mouse monoclonal anti-FLAG® M2 and rabbit anti-FLAG antibody
(both from Sigma-Aldrich), mouse anti-PDI (Abcam, Cambridge, UK),
rabbit anti-GFP [24] and rabbit monoclonal anti-17β-HSD1 (Ab51045,
Abcam, Cambridge, UK). Cells were then washed four times and
incubated for 30 min with Alexa Fluor® 488 goat anti-mouse IgG or
Alexa Fluor® 555 goat anti-rabbit. Where needed, Hoechst-33342 was
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Eugene, OR). After four washes with PBS, the cells were mounted in
Mowiol 4–88 and the slides were left to settle for several hours at
room temperature. Stainings were analyzed on an Olympus Fluoview
1000 laser scanning confocal microscope (Olympus, Center Valley, PA).
For the selective permeabilization experiments depicted in Table 1,
in order to determine the number of cells positive for antibody staining
with Triton X-100 and digitonin, around 1000 cells were counted per
sample in three independent experiments. With the calcium phosphate
transfection method employed in our lab, we have observed a transfec-
tion efﬁciency of about 25%, analyzed 48 h after transfection, when
using a vector for GFP expression. This has been calculated from the
total number of cells counted in a bright ﬁeld setting in comparison
with the cells expressing GFP. After ﬁxation of cells and perme-
abilization with 0.3% Triton X-100 for 5 min, the total number of cells
was determined by Hoechst-33342 nuclear staining. The percentage of
cells yielding a positive GFP signal after staining with a GFP-speciﬁc
antibody and the number of cells expressing GFP, determined as de-
scribed before, was almost identical. After having established that for
GFP-transfected cells, we concluded that the number of transfected
cells and the number of antibody-stained positive cells after Triton X-
100 permeabilization is essentially the same. The only exception was
FLAG-17β-HSD7 that showed lower expression levels, and the positive
control with Triton X-100 yielded 15% stained cells.2.4. Live cell microscopy and image analysis
Cells were transfected with the roGFP2-fusion expression plasmids
on glass bottom dishes (Ibidi GmbH, Martinsried, Germany). After
48 h, cells were washed twice with HEPES buffer pH 7.4, containing
5.5 mM glucose, the dishes were transferred to an Olympus Fluoview
1000 laser scanning confocal microscope and visualized using a
60× oil immersion objective (NA 1.40). The microscope was
equipped with a 405 nm laser diode and a 488 nm argon laser. The
pictures were taken with 512 × 512 pixels and the emission window
was 505–605 nm. Pictures were taken at the steady state, 1 min after
addition of 5 mM diamide and 5 min after addition of 20 mM dithio-
threitol (DTT). The indicated concentrations were used on the basis
of previous publications [19,23,24,26]. For every transfected cell in
the visual ﬁeld one region of interest (ROI) was chosen. The back-
ground signal at the two different wavelengths was selected as a sep-
arate ROI outside the regions containing cells. The intensity of this
signal was subtracted from the intensity value acquired for each
ROI. The 405/488 nm ratios were then determined from the average
signal intensities in background subtracted ROI.Table 1
Quantiﬁcation of selective permeabilization experiments for the full length 17β-HSDs. In
each experiment 1000 cells were counted. 11β-HSD1 and 11β-HSD2 were used in every
experiment as controls. The relative rate of digitonin positive cells represents the percent-
age of cells counted positivewith digitonin divided by the percentage of cells positivewith





Digitonin Relative rate of
digitonin positive
cells
11β-HSD1-FLAG 23.3 ± 2.1 1.3 ± 0.5 5.6 ± 2.2
11β-HSD2-FLAG 25.7 ± 1.6 24.0 ± 1.3 93.4 ± 3.3
17β-HSD2-FLAG 24.8 ± 1.3 22.4 ± 0.8 90.3 ± 2.4
17β-HSD6-FLAG 26.0 ± 0.3 23.9 ± 0.8 91.9 ± 3.3
17β-HSD7-FLAG 23.6 ± 0.9 21.9 ± 1.1 92.8 ± 2.0
FLAG-17β-HSD7 15.2 ± 2.1 2.7 ± 0.4 17.2 ± 2.1
17β-HSD11-FLAG 26.8 ± 2.2 25.6 ± 2.3 95.1 ± 1.0
17β-HSD12-FLAG 24.7 ± 2.3 23.7 ± 2.8 96.0 ± 3.0
17β-HSD13-FLAG 25.8 ± 2.4 25.0 ± 2.3 96.9 ± 1.5The degree of sensor oxidation (OxD) for the roGFP2 fusion proteins





Rox−Rð Þ þ R−Rredð Þ
where R, Rred and Rox represent the 405/488 nm ﬂuorescence ratios at
steady state, upon complete reduction or complete oxidation, respec-
tively, and Imin and Imax represent theﬂuorescence intensities of fully ox-
idized and fully reduced roGFP2 measured upon excitation at 488 nm.
The OxD value was calculated separately for every cell, and the values
shown in the graphs represent the average from all cells measured per
experiment, in three independent experiments.
2.5. In silico analysis
For the in silico analysis of the structure of different 17β-HSDs we
implemented the Kyte and Doolittle hydropathy score [45], using the
online tool: http://gcat.davidson.edu/DGPB/kd/kyte-doolittle.htm. For
the analysis of ΔG, z-coordinate and statistical analysis prediction we
used the TOPCONS site (http://topcons.cbr.su.se/) [46].
3. Results
3.1. Determination of 11β-HSD1 and 11β-HSD2 topology using roGFP2
fusion proteins
To investigate whether the degree of roGFP2 oxidation can be used
to assess the topology of ER membrane proteins, we took advantage of
two ERmembrane enzymes whose topology has already been resolved,
11β-HSD1 and 11β-HSD2 [27,28,30]. The C-terminus of 11β-HSD1 faces
the luminal side of the ER, whereas the C-terminus of 11β-HSD2 resides
in the cytosol. We expressed fusion proteins of full-length 11β-HSD1
and 11β-HSD2 with roGFP2 attached to the C-terminus in HEK-293
cells, followed by live imaging at steady state, after complete oxidation
of roGFP2 with diamide and complete reduction with DTT. The ratio of
ﬂuorescence intensity emission after excitation at 405 nm and 488 nm
was measured and the percentage of roGFP2 oxidation was calculated.
Representative images from the live cell measurements of the three dif-
ferent conditions are shown in Fig. 1. The ratio of ﬂuorescence intensity
at 405 nm and 488 nm of 11β-HSD1-roGFP2 was typical for a luminal
localization of the sensor, being relatively steady after addition of
diamide (since the protein exists already in an oxidized state) and
decreasing after reduction with DTT (Fig. 1A). In contrast, full length
11β-HSD2-roGFP2 exhibited a ratio typical of a cytosolic localization, in-
creasing upon oxidation and decreasing to basal levels upon reduction
(Fig. 1B). Calculation of the percentage of oxidation of roGFP2 was in
agreement, with 11β-HSD1-roGFP2 exhibiting a much higher degree
of oxidation compared to 11β-HSD2-roGFP2 (see also below, Fig. 5).
Based on the above results, we concluded that roGFP2 fusions can be re-
liably used for the determination of protein localization and topology.
3.2. Subcellular localization of 17β-HSD enzymes
After validating the roGFP2 fusion system using 11β-HSD proteins,
we applied it to determine the intracellular localization and topology
of the 17β-HSD family of enzymes, which comprises 14 members.
These enzymes not only have diverse functions, but also exhibit differ-
ent subcellular localization. In the present study, we focused on resolv-
ing themembrane topology of the 17β-HSD enzymes that are bound to
the ER membrane. 17β-HSD3 (SDR12C2) is an ER integral membrane
protein, and its topology was resolved recently [3]. Based on previous
work, 17β-HSD4 (SDR8C1) is located in peroxisomes, which is con-
sistent with its role in β-oxidation of fatty acids [43,47]. 17β-HSD8
(SDR30C1) and 17β-HSD10 (SDR5C1) have been shown to localize in
Fig. 1. Live cell-imaging of 11β-HSD1-roGFP2 and11β-HSD2-roGFP2.ΗΕΚ-293 cells expressing either full length 11β-HSD1or 11β-HSD2, both containing C-terminal roGFP2,were imaged
by laser-scanning confocal microscopy after excitation with 405 nm and 488 nm lasers at steady state and upon sequential addition of diamide and DTT. Representative images of the
staining intensity and depiction of the ratios of 405/488 nm emitted ﬂuorescence intensities for 11β-HSD1-roGFP2 (A) and 11β-HSD2-roGFP2 (B). Results shown in the bar graphs rep-
resentmean±S.D. from three independent experiments, after analysis of 8–10 cells per experiment. Student's t-testwas performed to estimate the signiﬁcance of thedifferences between
the steady-state and oxidation or reduction (***p b 0.001, ns: non-signiﬁcant).
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earlier to be a cytosolic protein and does not possess a putative trans-
membrane region [50]. 17β-HSD1 has been regarded to be a cytosolic
protein based on its amino acid sequence. 17β-HSD1 is not predicted
to possess transmembrane helices. Using a speciﬁc antibody against
the protein we found that it does not exhibit a typical ER pattern and
appears to be predominantly cytosolic. Based on our immunostaining,
potential attachment to intracellular membranous organelles cannot
be excluded (Fig. 2). In addition, we tested the degree of oxidation of
17β-HSD1-roGFP2, which is consistent with cytosolic localization (see
also below, Fig. 5). All the above enzymes were, therefore, not further
considered in the present study. Expression of C-terminally FLAG-
tagged 17β-HSD2, 17β-HSD6, 17β-HSD7 and 17β-HSD12 resulted in a
typical ER pattern, which was shown by localization of the FLAG-
tagged proteins at the same cellular compartment as the ER-residentprotein PDI (Fig. 2). 17β-HSD11 and 17β-HSD13 are present in the ER,
andwere shown to also occupy organelles of lipid storage andmobiliza-
tion, known as lipid droplets [51,52]. To verify the intracellular localiza-
tion of these two enzymes, we expressed in HEK-293 cells 17β-HSD11
and 17β-HSD13 bearing a FLAG epitope at the C-terminus. Staining
with anti-FLAG antibody showed a typical ER pattern, with occasional
presence of the proteins in lipid droplets. Importantly, addition of
oleic acid, which promotes lipid droplet formation, resulted in re-
localization of 17β-HSD11 and 17β-HSD13 into lipid droplets (Fig. 3).
3.3. In silico analysis of the structural architecture of 17β-HSDs that reside
at the ER
To gain insight into the structure of the different enzymes, we ﬁrst
implemented the Kyte and Doolittle quantitative method for the
Fig. 2. Subcellular localization of 17β-HSDs. 17β-HSD1, 17β-HSD2-FLAG, 17β-HSD6-FLAG,
17β-HSD7-FLAG and17β-HSD12-FLAGwere expressed in HEK-293 cells and stained with
rabbit anti-17β-HSD1 antibody and Hoechst-33342 dye for 17β-HSD1 or anti-mouse PDI
and anti-rabbit FLAG for 17β-HSD2-FLAG, 17β-HSD6-FLAG, 17β-HSD7-FLAG and17β-
HSD12-FLAG. Representative confocal images of the localization of proteins are shown
(anti-17β-HSD: green, Hoechst-33342: red, FLAG: green, PDI: red).
Fig. 3. Subcellular localization of 17β-HSD11 and 17β-HSD13. HEK-293 cells were
transfected with constructs encoding for 17β-HSD11-FLAG and 17β-HSD13-FLAG and
left untreated or treated with oleic acid for 16 h to trigger formation of lipid droplets. At
48 h post-transfection cells were immunostained with rabbit anti-FLAG antibody and
mouse anti-PDI antibody. Representative confocal images of the immunostainings are
shown (FLAG: green, PDI: red).
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(Fig. 4). High hydrophobicity scores in parts of the protein indicate po-
tential membrane-spanning segments. In addition, we employed the
ΔG prediction algorithm, which determines the apparent free energy
difference for insertion of a sequence into the ER membrane by the
Sec61 translocon [53]. This is combined with the depiction of the abso-
lute value of the Z-coordinate, representing the predicted distance of a
residue from the membrane center [54]. The TOPCONS algorithmcombines ﬁve different algorithms of topology prediction into one
consensus prediction [46]. Based on the models above, the 17β-HSD
enzymes tested are predicted to contain one (or two in the case of
17β-HSD2) transmembrane helix very close to the N-terminus, with
the exception of 17β-HSD7,which has a single putative transmembrane
segment starting at around two thirds of its sequence. As described
later, the presence of this transmembrane sequence and the transmem-
brane sequences close to the N-terminus for the remaining 17β-HSDs
are in accordance with our results. Our experimental data additionally
implies the presence of another transmembrane sequence close to the
C-terminus for 17β-HSD6 and 17β-HSD12. The TOPCONS algorithm
correctly predicts this second transmembrane sequence for 17β-HSD6,
which, however, is not undoubtedly deﬁned by the rest of the parame-
ters tested, such as the ΔG. Also, TOPOCONS does not predict a second
transmembrane segment for 17β-HSD12. However, the hiddenMarkov
model prediction algorithm TMHMM supports the presence of this sec-
ond transmembrane sequence, and so does the SCAMPI algorithm [55],
which is based on the position-speciﬁc contribution of individual amino
acids in the free-energy ofmembrane insertion. Besides, the hydropathy
Fig. 4. In silico analysis of 17β-HSD structure. TheKyte andDoolittle hydropathy plots depicted at the topwere acquired using awindowsize between9 and11. The absolute values of the z-
coordinate are shown on the left y axis (values range: 0–25 Å) and the ΔG values on the right y axis. The prediction of TOPCONS regarding the putative transmembrane segments is illus-
trated (the TOPCONS prediction regarding in and out orientation is not shown). At the bottom of each panel the putative transmembrane sequences and topology suggested by our
experimental data is shown. Cytosolic parts of proteins are shown in black and luminal parts in gray.
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the cytosol) orientation for the different sequences of the enzymes test-
ed, we employed several prediction algorithms, including TOPCONS.
However, we were not able to validate or disprove our results based
on these analyses, since the predictions given by individual algorithms
largely disagree. For this reason, the in–out prediction of the TOPCONS
algorithm is not depicted.
3.4. Determination of the topology of 17β-HSDs at the ER membrane
First, we investigated the orientation of the C-terminus of the select-
ed 17β-HSDs upon expression of full length roGFP2 fusions in HEK-293
cells and performing live cell imaging experiments 48 h after transfec-
tion. Based on the degree of oxidation of roGFP2, which varied between8% and 20%, we concluded cytosolic orientation for the C-terminus of
17β-HSD2, 17β-HSD6, 17β-HSD7, 17β-HSD11, 17β-HSD12 and 17β-
HSD13 (Fig. 5). All the enzymes, with the exception of 17β-HSD7, are
predicted to have a transmembrane region 3–6 amino acids after the
N-terminus. As depicted in Fig. 4, for some of the enzymes the presence
of a second transmembrane region cannot be excluded, implying that
the C-terminus and the active site of the enzymes could lie in different
compartments. In order to investigate the compartment in which the
co-factor binding site and active site of these enzymes reside (which
appear after the ﬁrst transmembrane region), we created truncated
versions of the enzymes, in which roGFP2 is placed downstream the
ﬁrst transmembrane region thus replacing the co-factor binding site
and active site. These proteins were named 17β-HSD2 (aa 1–88), 17β-
HSD6 (aa 1–35), 17β-HSD11 (aa 1–42), 17β-HSD12 (aa 1–56) and
Fig. 5. Live cell imaging of roGFP2 fusion proteins. Fusion proteins with roGFP2 of 11β-
HSD1, 11β-HSD2, 17β-HSD1, 17β-HSD2, 17β-HSD2 (aa 1–88), 17β-HSD6, 17β-HSD6
(1–35), 17β-HSD7, 17β-HSD11, 17β-HSD11 (aa 1–42), 17β-HSD12, 17β-HSD12 (1–56),
17β-HSD13 and 17β-HSD13 (aa 1–42) were expressed in HEK-293 cells. The samples
were imaged 48 h post-transfection after excitation with 405 and 488 nm lasers at steady
state, upon addition of diamide andDTT. The percentage of oxidation of roGFP2was calcu-
lated and plotted (mean± S.D. from three independent experiments). The group ‘a’ refers
to proteins scored as luminal and the group b refers to proteins scored as cytoplasmic.
Student's t-test showed that the difference among proteins belonging to the same group
is not signiﬁcant. The difference between proteins of groups a and b is signiﬁcantly differ-
ent with p ≤ 0.01.
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proteins revealed cytosolic localization for 17β-HSD2 (aa 1–88), 17β-
HSD11 (aa 1–42) and 17β-HSD13 (aa 1–42). The percentage of oxida-
tion of 17β-HSD11 (aa 1–42) was higher than usually observed for
cytosolic proteins. The increased degree of oxidation of 17β-HSD11
(1–42) roGFP2 could be explained if a small fraction of this truncated
protein was mislocalized. Another possible explanation could be that
the speciﬁc microenvironment in which this truncated protein lies is
slightly more oxidized in comparison to the rest of the cytosol. Luminal
localization was observed for 17β-HSD6 (aa 1–35) and 17β-HSD12 (aa
1–56). The fact that these two enzymes exhibited cytosolic localization
of the C-terminus, points towards the presence of a second transmem-
brane region, which would result in the active site and the C-terminus
having different localizations.
Next, we sought to validate the results obtained with the roGFP2
fusions, with an independent method, i.e. selective permeabilization
of cell membranes followed by immunoﬂuorescence detection. For
these experiments we used proteins tagged with the FLAG epitope, in
order to investigate whether the presence of roGFP2 would affect the
topology of the proteins with which it is fused. To conﬁrm the results
obtained from the full length roGFP2 fusions, we expressed full length
C-terminally FLAG-tagged proteins in HEK-293 cells and selectively
permeabilized cell membranes using digitonin or completely perme-
abilized with Triton X-100. In addition, 11β-HSD1 C-terminally tagged
with FLAG (11β-HSD1-FLAG) was used as a luminal control and 11β-
HSD2 C-terminally tagged with FLAG (11β-HSD2-FLAG) as a cytosolic
control. After immunoﬂuorescence staining against the FLAG epitope,
the results were analyzed with ﬂuorescence microscopy. Fig. 6 shows
representative confocal images. The quantiﬁcation of three independent
experiments is given in Table 1. In the case of 17β-HSD2, 17β-HSD6,
17β-HSD7, 17β-HSD11, 17β-HSD12 and 17β-HSD13, the percentage
of cells stained positive after treatment with digitonin or Triton X-100
were comparable, indicating a cytosolic localization of the C-terminus
of these enzymes. The existence of dual/multiple orientations is unlikely
for these enzymes, since this would be expected to result in a signiﬁ-
cantly lower number of positive cells with digitonin in comparison toTriton X-100. Importantly, the above results are in accordance with
the data obtained from the roGFP2 experiments.
To attempt to validate the results obtained with the truncated
roGFP2 fusions, we created truncated FLAG-tagged versions of 17β-
HSD6 and17β-HSD12, which showed rather low expression levels
upon transfection. This made it impossible to draw reliable conclusions
from selective permeabilization experiments using these proteins. To
overcome this issue, we performed selective permeabilization experi-
ments utilizing the truncated roGFP2 proteins and this time assessing
the accessibility of the anti-GFP antibody. In these experiments we
could directly conclude on the number of transfected cells based on
the presence of ﬂuorescence emitted by roGFP2. Parallel analysis
showed that 100% of transfected cells are stained with the anti-GFP
antibody after Triton X-100 permeabilization. Therefore, for the quan-
tiﬁcation of cells stained with the anti-GFP antibody after digitonin
permeabilization, we calculated the percentage of transfected cells
(showing ﬂuorescence because of roGFP2) that were also stained with
the anti-GFP antibody (Table 2). Our results revealed cytosolic localiza-
tion for 17β-HSD2 (aa 1–88), 17β-HSD11 (aa 1–42) and 17β-HSD13 (aa
1–42) and luminal localization for 17β-HSD6 (aa 1–35) and 17β-HSD12
(aa 1–56). These results agree with those from the live imaging experi-
ments using the truncated roGFP2 fusions.
As mentioned above, 17β-HSD7 is not predicted to contain an N-
terminal transmembrane region, while a putative transmembrane
helix seems to exist downstream of the active site. Therefore, for 17β-
HSD7 itwasnot possible to directly determine the compartmental local-
ization of the active site by creating a truncated form of the protein.
17β-HSD7 tagged with roGFP2 at the C-terminus exhibited a cytosolic
orientation (Fig. 5), which was supported by selective permeabilization
experiments of 17β-HSD7-FLAG (Fig. 6 and Table 1). In order to investi-
gate the topology of the active site of the enzyme, we added a FLAG
epitope tag at the N-terminus of 17β-HSD7. The expression of this con-
struct was lower in comparison with the other constructs, possibly due
to inefﬁcient synthesis and/or insertion into the ERmembrane or partial
degradation of the N-terminally tagged protein. Although the rate of
digitonin positive cells is higher than in other cases of luminal proteins,
experiments with selective permeabilization are suggestive of luminal
localization of the FLAG epitope (Fig. 6 and Table 1). Since addition of
epitope tags at the N-terminus of a protein could affect localization,
due to the potential presence of signal peptides and other N-terminal
determinants, we sought to conﬁrm that in the FLAG-17β-HSD7 the C-
terminus was cytosolic, as found in the previous experiments. For this
purpose, we created the same construct containing at the C-terminus
the roGFP2 sequence (FLAG-17β-HSD7-roGFP2). The degree of oxida-
tion of roGFP2 in this protein was suggestive of a cytosolic localization
of the sensor (not shown), which supports that the N-terminal FLAG
epitope did not affect the orientation of the C-terminus. The above re-
sults suggest that the active site of 17β-HSD7 protrudes into the ER
lumen, while its C-terminus is facing the cytosol.
4. Discussion
Elucidation of the exact topology of membrane proteins is necessary
for understanding important aspects of their biological functions.
The methods used so far to determine membrane protein topology
are based on arduous biochemical procedures, such as selective-
permeabilization of cellular membranes followed by immunodetection
and proteinase K treatment, which involves post-lysis manipulation of
cells. On the other hand, ﬂuorescence-based methods such as the ﬂuo-
rescence protease protection assay [16,17] and the protein complemen-
tation assay [18] are invasive or require co-expression of two proteins
that bear two halves of YFP, and subsequent reconstitution of full length
YFP. Recently, a new method for topology assessment was developed
based on a glycosylatable GFP variant [56], which can also be used to
assess topology of ER membrane proteins in live cells [57]. Since
this method relies on the N-glycosylation of GFP rendering it non-
Fig. 6. Determination of the membrane topology of full length 17β-HSD2, 17β-HSD6, 17β-HSD7, 17β-HSD11, 17β-HSD12 and 17β-HSD13 by selective permeabilization. HEK-293 cells
were transfected with expression plasmids coding for the indicated constructs. All proteins bear the FLAG tag at the C-terminus, except for FLAG-17β-HSD7, which bears an N-terminal
FLAG tag. At 48 h post-transfection cells were ﬁxed, permeabilized with 14 μM digitonin or 0.3% Triton X-100 and stained with the anti-FLAG antibody M2, followed by incubation
with Alexa Fluor®488 antibody and Hoechst-33342 dye. Fluorescence was analyzed using confocal laser-scanning microscope and representative images from one experiment are
shown (FLAG: green, Hoechst-33342: magenta).
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GFP glycosylation upon fusion with the protein of interest is essential.
Althoughmore time consuming than the approach presented in the cur-
rent study, the use of glycosylatable GFP variants may be advantageous
for special cases where a given protein has multiple orientations.
Here, we report a straightforward and rapid method for the analysis
of the topology of ERmembrane proteins, based on the fusion of roGFP2
with the protein of interest. The results show that the degree of oxida-
tion of roGFP2 correlates with the redox status of the environment in
which it resides (more reduced in the cytosol and more oxidized in
the ER lumen). The degree of oxidation of roGFP2 alters its emission
peaks after excitation at two differentwavelengths. Theﬂuorescence in-
tensity at these two wavelengths at the steady state and after subse-
quent addition of an oxidizing and a reducing agent can then be used
to calculate the oxidation status of roGFP2. The method described in-
volves the generation of a single fusion protein and requires a confocal
microscope equipped with two common laser lines, at 405 nm andTable 2
Quantiﬁcation of selective permeabilization experiments for the truncated 17β-HSD-
roGFP2 fusions. In each experiment 500 cells expressing roGFP2 were counted and
assessed for anti-GFP staining after digitonin treatment. Full length 11β-HSD1-roGFP
and 11β-HSD2-roGFP were used in every experiment as controls. Data represent
mean ± S.D. from three independent experiments.
Expressed protein % of digitonin positive cells
11β-HSD1-roGFP2 8.3 ± 0.9
11β-HSD2 -roGFP2 95.1 ± 2.0
17β-HSD2 (1–88)-roGFP2 96.1 ± 1.7
17β-HSD6 (1–35)-roGFP2 7.8 ± 1.3
17β-HSD11 (1–42 )-roGFP2 89.8 ± 1.4
17β-HSD12 (1–56 )-roGFP2 12.1 ± 1.4
17β-HSD13 (1–42 )-roGFP2 94.4 ± 2.4488 nm. The measurement is non-invasive, since it is performed in
living cells. In addition, the duration of the live measurement is short
(10 min), allowing the analysis of several different samples in one ex-
perimental setting. The ﬂuorescence intensitymeasurement is provided
automatically by the confocal microscope analytical software, and
the calculation of the ratio and OxD value is rather simple. This allows
for both efﬁcient data acquisition and processing. It has been reported
that certain roGFP variants exhibit a dim ﬂuorescence signal, and also
that the baseline measurements can vary due to light-induced oxida-
tion, which results in slight differences of the steady-state ratio of ﬂuo-
rescence between individual experiments [58,59]. Using roGFP2, we
have not encountered problems of ﬂuorescence intensity and since
our experiments are performed in darkness, the steady-state ﬂuores-
cent levels of the sensor do not show signiﬁcant variations between
experiments.
As proof of principle, we applied the roGFP2 fusion method and
conﬁrmed the topology of 11β-HSD1 and 11β-HSD2, two enzymes
with known ER membrane topology [27–30] that essentially catalyze
the local availability of active glucocorticoids to corticosteroid receptors
[60]. In a next step, we determined the topology of enzymes of the 17β-
HSD family (results summarized in Fig. 7). This constitutes a functional-
ly diverse group of enzymes, some shown to play a pivotal role in sex
steroid metabolism (17β-HSD1, 2, 3, 4, 5, 6, 7, 12 and 14). Due to their
function in regulating androgen and estrogen metabolism, differences
in the expression and/or function of these enzymes are linked with de-
velopmental disorders, sex-speciﬁc syndromes and various types of
cancers [31]. For example, 17β-HSD2 is involved in the oxidation of
the active estrogen estradiol to its inactive form estrone and has been
implicated in the development of colon and breast cancer [61–66]. Fur-
thermore, 17β-HSD2 inhibitors are evaluated for the treatment of oste-
oporosis, a diseasemainly affecting postmenopausalwomen. A previous
study suggested that 17β-HSD2 is an ER luminal enzyme [67]. This was
Fig. 7. Schematic representation of the topology of 17β-HSD enzymes. The co-factor binding site (Rossman fold) and active site of 17β-HSD2, 17β-HSD3, 17β-HSD11 and 17βHSD-13
is facing the cytosol, whereas that of 17β-HSD6, 17β-HSD7 and 17β-HSD12 protrudes into the ER lumen. 17β-HSD1 does not possess a transmembrane region and is cytosolic. The
topology of 11β-HSD1 and 11β-HSD2 that has been resolved previously is also depicted. The asterisk indicates the two 17β-HSDs that are also present in the lipid droplets (17β-
HSD11 and 17β-HSD13).
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retentionmotif in the carboxyl terminus, whichwas presumed to direct
this part in the ER. A second study also supported luminal orientation of
17β-HSD2 based on an experiment using confocal microscopy and
showing co-staining of 17β-HSD2 with the ER-resident protein BiP
[68]. However, the resolving power of the confocal microscope by no
means allows determination of a protein topology in a biological mem-
brane. Thus, solid experimental data for the topology of 17β-HSD2 has
been so far lacking. Our live-imaging measurements using 17β-HSD2-
roGFP2 and 17β-HSD2 (1–88)-roGFP2 combined with the selective
permeabilization experiments clearly demonstrate that this enzyme
possesses an N-terminal membrane anchor and that its catalytic moiety
and C-terminus are facing the cytosol. In this case, the roGFP2 fusion
method allowed re-evaluation of previous topology ﬁndings.
In addition, we showed that 17β-HSD11 and 17β-HSD13, integral ER
membrane proteins that are also found in lipid droplets, are facing the cy-
tosol. This result was expected, since to our knowledge there is no
regenerating system existing in lipid droplets for NADPH, an essential co-
factor for the enzymatic activity of both proteins. De novo formation of
lipid droplets is believed to occur through budding from the outer mem-
braneof the ER. The precisemechanismof lipid droplet formation, includ-
ing the manner by which ER membrane proteins are redirected to the
lipid monolayer of lipid droplets, is not fully elucidated [69,70]. For such
studies, knowledge of membrane protein topology could prove useful.
Our results further show that 17β-HSD6 has its active site in the ER
lumen,while its very C-terminal part protrudes into the cytosol. This en-
zyme is believed to play a role in the synthesis of the potent androgen
dihydrotestosterone in a pathway by-passing testosterone production
(the so-called ‘backdoor pathway’) [71,72]. Furthermore, 17β-HSD6
was found to be down-regulated in prostate cancer [73]. Thus, the struc-
tural and functional study of this enzyme, including the elucidation of its
dependence on the luminal NAD+pool, could provide important insight
into androgen metabolism and steroid changes occurring in prostate
cancer.
Another interesting member of the 17β-HSD family is 17β-HSD7,
which was shown to be highly expressed in breast cancer tissues
[74]. It is able to convert estrone to estradiol [75,76] and also pos-
sesses 3-ketosteroid reductase activity by catalyzing the conversion
of zymosterone to zymosterol [42,77], the latter being an essential
step in de novo cholesterol synthesis. Our results demonstrate that the
C-terminus of 17β-HSD7 protrudes into the cytosol, whereas its N-
terminus and the active site are in the ER lumen. 17β-HSD12 is anothermulti-functional enzyme able to convert estrone to estradiol [78] and
also participating in the second step of long-chain fatty acid elondation,
by reducing 3-ketoacyl-CoA to hydroxylacyl-CoA [41]. Its expression
has been correlated with poor prognosis in breast and ovarian cancer,
which is believed to be linked with its role in fatty acid synthesis rather
than its ability to convert estrone to estradiol [79,80]. Our data shows
that the active site of 17β-HSD12 is facing the ER lumen. Western
blot assays in two previous publications have identiﬁed two sepa-
rate bands relating to the protein, which are postulated to represent
its N-glycosylated and unglycosylated forms [81,82]. The potential N-
glycosylation site resides in the part of the protein that according
to our data faces the ER. This is consistent with the fact that N-
glycosylation takes place in the ER lumen. Previously published hydro-
phobicity index calculations also support the possibility of one trans-
membrane domain close to the beginning of the protein and one near
the end [41], although the in silico analysis as shown in Fig. 4 does not
yield unambiguous predictions, thus, experimental validation is neces-
sary. Better understanding the physiology and function of 17β-HSD7
and 17β-HSD12 could provide important insight into their role in the
vital biological processes of cholesterol synthesis and very long-chain
fatty acid elongation, as well as into their involvement in breast cancer.
Besides 17β-HSDs, the vast number of ER membrane proteins is re-
sponsible for an array of different functions, including calcium homeo-
stasis, protein folding, post-translational modiﬁcations and essential
metabolic reactions. The topology of these proteins is closely related
with their function. A good example is the conversion of cholesterol to
cholesterol esters. This reaction can be performed by two isoforms of
acyl-CoA:cholesterol acyltransferase (ACAT), ACAT1 and ACAT2. The ac-
tive site of ACAT1 faces the cytosolwhere cholesterol esters are stored in
lipid droplets. On the other hand, ACAT2 faces the ER lumen, in which
cholesterol esters are stored as apo-B-containing lipoprotein particles
[83]. Thus, the differential topology of the two ACAT isoforms deter-
mines their functional speciﬁcity. Isoform-speciﬁc inhibitors of the
ACAT enzymes are currently considered for treatment of atherosclerosis
through a reduction in blood cholesterol levels. Appropriate access of
such inhibitors to the respective compartment needs to be considered
in drug development.
5. Conclusions
We developed a non-invasive and rapid method using the roGFP2
ratiometric sensor for determination of ER membrane protein topology
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different studies. In our work, we generated an expression vector that
tags the roGFP2 at the C-terminus of the proteins of interest. Despite
the advantages of the method described here, we cannot exclude that
in certain cases fusionwith roGFP2might alter the folding and/or topol-
ogy of a protein. Based on our validation experiments using selective
permeabilization, this was not the case for any of the proteins tested
in this study. With the appropriate design, addition of roGFP2 is also
possible at the N-terminus. However, this in some cases may disturb
correct localization, bymasking signal peptides and other determinants
located near the N-terminus. Caution should be taken for proteins that
contain speciﬁc retention/retrieval signals at the C-terminus, such as
the KDEL, KKXX or SKL motifs, since addition of any C-terminal tag
will most likely alter their subcellular distribution. The same holds
true for tail-anchored protein targeting, where C-terminal tags can dis-
rupt the cellular machinery involved in their proper integration in the
ER membranes. Testing whether addition of roGFP2 affects subcellular
localization of a protein of interest is necessary, since the roGFP2
method was developed for ER membrane protein topology rather than
subcellular localization assessment. Truncated forms of membrane pro-
teins can be tested, since fusion to roGPF2 did not change the subcellular
localization of truncated compared to full-length proteins. Fusion to
roGFP2 seems to stabilize truncated forms of proteins, potentially
through rendering the resulting proteins longer. Truncated versions of
the same proteins tagged with FLAG exhibited very poor expres-
sion levels. Furthermore, with this method the complete topology of
polytopic proteins can be dissected by adding roGFP2 before and after
each transmembrane region. An interesting option for future studies re-
mains to test the applicability of roGFP2 fusions for resolving the topol-
ogy of proteins residing in other cellular compartments.
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